The latest price target for eFFECTOR Therapeutics (OTCEM:EFTR) was reported by HC Wainwright & Co. on March 28, 2024. The analyst firm set a price target for $24.00 expecting EFTR to rise to within 12 months (a possible 30551.34% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for eFFECTOR Therapeutics (OTCEM:EFTR) was provided by HC Wainwright & Co., and eFFECTOR Therapeutics reiterated their buy rating.

The last upgrade for eFFECTOR Therapeutics Inc happened on May 26, 2023 when Stifel raised their price target to $7. Stifel previously had a hold for eFFECTOR Therapeutics Inc.

The last downgrade for eFFECTOR Therapeutics Inc happened on January 25, 2022 when Stifel changed their price target from $20 to $6.2 for eFFECTOR Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of eFFECTOR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for eFFECTOR Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.

While ratings are subjective and will change, the latest eFFECTOR Therapeutics (EFTR) rating was a reiterated with a price target of $24.00 to $24.00. The current price eFFECTOR Therapeutics (EFTR) is trading at is $0.08, which is out of the analyst’s predicted range.